Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.8K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.8K
Allergic Reactions02:06

Allergic Reactions

32.1K
Overview
32.1K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.1K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.1K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden-A SANI Multicenter Cohort.

Journal of personalized medicine·2026
Same author

Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry.

The Lancet. Respiratory medicine·2026
Same author

Allergen Immunotherapy for the Treatment of Eosinophilic Esophagitis. An EAACI Task Force Systematic Review.

Clinical and translational allergy·2026
Same author

Fractional exhaled nitric oxide and nasal nitric oxide as biomarkers in chronic rhinosinusitis.

Current opinion in allergy and clinical immunology·2026
Same author

Clinical outcomes and remission trajectories in obese and non-obese patients with severe asthma treated with biologics: a retrospective longitudinal cohort study from the Severe Asthma Network Italy (SANI) registry.

The Lancet regional health. Europe·2026
Same author

Clinical remission in allergy and clinical immunology practice: State of the art and World Allergy Organization (WAO) call to action.

The World Allergy Organization journal·2026

相关实验视频

Updated: Jan 17, 2026

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.3K

过敏原免疫疗法:对肺功能有效吗?

Edoardo Cavaglià1,2, Maurizio Marogna3, Giovanni Paoletti1,2

  • 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele.

Current opinion in allergy and clinical immunology
|September 18, 2025
PubMed
概括
此摘要是机器生成的。

过敏原免疫疗法 (AIT) 显示出持续性喘益处的潜力,并可能改善肺功能,但强有力的长期证据仍然有限. 需要进一步的研究来确认其在改变喘进展中的作用.

关键词:
过敏原免疫疗法 免疫疗法喘 喘 是一种疾病的修改 疾病的修改肺功能 肺功能 肺功能语言下免疫疗法免疫治疗

更多相关视频

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

2.9K
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

3.9K

相关实验视频

Last Updated: Jan 17, 2026

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.3K
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

2.9K
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

3.9K

科学领域:

  • 肺部病理学 肺部病理学
  • 免疫学 免疫学 免疫学
  • 过敏 过敏是一种过敏.

背景情况:

  • 喘管理正在向针对2型炎症的疾病修饰策略发展.
  • 过敏原免疫疗法 (AIT) 是对过敏性疾病的关键干预措施.
  • 了解AIT对喘进展的长期影响至关重要.

研究的目的:

  • 审查对过敏原免疫治疗对喘患者肺功能影响的证据.
  • 专注于喘患者AIT的长期结果.
  • 评估AIT在喘疾病修饰中的潜在作用.

主要方法:

  • 对观察性和随机对照研究的系统审查.
  • 分析临床益处,喘控制,恶化率和肺功能.
  • 包括最近的现实世界前性研究.

主要成果:

  • 语言下免疫疗法 (SLIT) 可能提供持续的临床益处和对肺功能的积极影响.
  • 观察到喘控制和减轻恶化情况的持续改善.
  • 对长期肺功能保护的有力证据是有限的;一些研究表明对FEV1.1的过敏原独立益处.

结论:

  • AIT被确认为一种针对过敏症的疾病修饰治疗方法.
  • 对于AIT能够预防或减缓喘中的肺功能下降的能力,需要进一步研究.
  • 未来的研究应该集中在各种过敏原和人群的纵向螺旋测量数据上,以澄清AIT在喘进展中的作用.